New Phase 3 Trial to Test Nuplazid for Parkinson’s Psychosis in Array of Dementia Patients

(October 12, 2017) – Acadia Pharmaceuticals is starting a new Phase 3 clinical trial testing the efficacy of pimavanserin to treat the hallucinations and delusions associated with dementia-related psychosis in a broad array of patients with Parkinson’s, Alzheimer’s, and many other dementias. Read more…